Recent investigations have centered on the overlap of GLP-1|GIP|GCGR agonist therapies and DA neurotransmission. While GCGR activators are increasingly employed for addressing type 2 diabetes, their emerging impacts on reinforcement circuits, specifically governed by dopamine networks, are receiving considerable focus. This report presents a concis